Aptinyx Inc

Aptinyx Inc. is a clinical stage biopharmaceutical company, which engages in discovery, development, and commercialization of transformative therapies for disorders of the brain and nervous system. Its product includes NYX-2925, NYX-783, NYX-458, and the AGN-241751 program. The company was founded by Norbert G. Riedel and Joseph R. Moskal in June 2015 and is headquartered in Evanston, IL.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the completion of enrollment in the company's ongoing Phase 2b study of NYX-2925 for the treatment of painful diabetic peripheral neuropathy (DPN). Patients recently enrolled in the study are completing the 12-week treatment period and 30-day safety follow-up period. The company expec

Aptinyx Completes Enrollment in Phase 2b Study of NYX-2925 in Painful Diabetic Peripheral Neuropathy

EVANSTON, Ill--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Tuesday, November 9, 2021 at 5:00 p.m. ET to report third quarter 2021 financial results and discuss recent business highlights. To access the live conference call, please dial (844) 200 6205 (domestic) or (929) 526 1599

Aptinyx to Report Third Quarter 2021 Financial Results on Tuesday, November 9, 2021

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced the appointment of Gilmore O'Neill, M.B., M.M.Sc., to the company's board of directors. Dr. O'Neill currently serves as chief medical officer and executive vice president of research and development at Sarepta Therapeutics. “Gilmore brings an exceptional background of experience and leadership

Aptinyx Appoints Gilmore O'Neill, M.B., M.M.Sc., to Board of Directors

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Norbert Riedel, Ph.D., chief executive officer, will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference on September 30, 2021 at 10:00 a.m. ET. A live webcast of the presentation will be available to view on the “Events and Presentations” page

Aptinyx to Participate in 2021 Cantor Virtual Global Healthcare Conference

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that it has entered into a $50 million loan facility and security agreement with K2 HealthVentures (K2HV). The funds will provide general growth capital as Aptinyx advances its late-stage clinical pipeline of novel NMDA modulators. “Access to this capital provides us with additional f

Aptinyx Secures $50 Million Growth Capital Credit Facility from K2 HealthVentures

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that company management will present at the H.C. Wainwright 23rd Annual Global Investment Conference to be held virtually September 13-15, 2021. The presentation will be available on-demand through the H.C. Wainwright conference portal, beginning at 7:00 AM ET on Monday, September 13, 2021. A l

Aptinyx to Participate in H.C. Wainwright 23rd Annual Global Investment Conference

Aptinyx Inc. (APTX) CEO Norbert Riedel on Q2 2021 Results - Earnings Call Transcript

EVANSTON, Ill.--(BUSINESS WIRE)--In the Condensed Balance Sheet, last line should read: Total liabilities and stockholders' equity   $ 134,168   $ 150,606 instead of: Total liabilities and stockholders' equity   $ 134,169   $ 150,606 The updated release reads: APTINYX REPORTS SECOND QUARTER 2021 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS Enrollment on track in both Phase 2b chronic pain studies with NYX-2925—data readouts expected 1H 2022 Enrollment on track in Phase 2 cognitive impairment study

CORRECTING and REPLACING Aptinyx Reports Second Quarter 2021 Financial Results and Business Highlights

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today reported financial results for the second quarter of 2021 and provided key business updates. “We continue to make good progress in advancing our pipeline programs to enable multiple important Phase 2 data readouts in 2022,” said Norbert Riedel, PhD, chief executive officer of Aptinyx. “With several trans

Aptinyx Reports Second Quarter 2021 Financial Results and Business Highlights

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that Norbert Riedel, Ph.D., chief executive officer, will participate in the “Brains of the Operation - Novel Approaches in Neuro” panel discussion at the Wedbush PacGrow Healthcare Virtual Conference on Tuesday, August 10 at 12:00 p.m. ET. A live webcast of the presentation will be available t

Aptinyx to Participate in 2021 Wedbush PacGrow Healthcare Virtual Conference

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that the company will host a conference call and live webcast on Tuesday, August 10, 2021 at 5:00 p.m. ET to report second quarter 2021 financial results and discuss recent business highlights. To access the live conference call, please dial (833) 772-0394 (domestic) or (236) 738-2205 (internat

Aptinyx to Report Second Quarter 2021 Financial Results on Tuesday, August 10, 2021

APTX stock went into long-term depression following a failed trial in 2019.

Aptinyx: CNS Drug Discoverer With Depressed Price

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that Norbert Riedel, Ph.D., chief executive officer, will participate in the Updates in Neuropysch panel discussion at the William Blair Biotech Focus Conference on Thursday, July 15 at 12:00 p.m. ET. A live webcast of the presentation will be available to view on the “Events and Presentations”

Aptinyx to Participate in William Blair Biotech Focus Conference 2021

When you're shopping for ground-floor biotech opportunities, it pays to be patient and diligent. APTX stock is looking good here.

Aptinyx Stock Looks Promising If You're Willing to Be Patient

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that management will participate in a fireside chat at the Cowen Psychedelics & Novel Mechanisms in Neuropsychiatry Summit on Tuesday, July 13 at 3:40 p.m. ET. A live webcast of the event will be available to clients of Cowen. About Aptinyx Aptinyx Inc. is a clinical-stage biopharmaceutical

Aptinyx to Participate in Cowen Psychedelics & Novel Mechanisms in Neuropsychiatry Summit

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that the Company will be participating in two upcoming investor conferences: Oppenheimer Biotech by the Lake 2021 Investor Summit – Norbert Riedel, Ph.D., chief executive officer, will participate in the “Hot Topics in Neurological Disorder Therapeutics and Technologies” Panel discussion on Tue

Aptinyx to Participate in Upcoming Investor Conferences

After a Type C meeting with the FDA, Aptinyx Inc (NASDAQ: APTX) has finalized the design of its Phase 2b program for NYX-783 in patients with post-traumatic stress disorder (PTSD). The program will consist of two separate studies to evaluate NYX-783 at two dose levels: 50 mg (Study 1) and 150 mg (Study 2).

Aptinyx Provides Updates On Mid-Stage NYX-783 Program In PTSD Patients

The stock price of Aptinyx Inc. (Nasdaq: APTX) fell by over 10% pre-market. This is why it happened.

APTX Stock Price Falls Over 10% Pre-Market: Why It Happened

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that it has finalized the design of its Phase 2b program for NYX-783 in patients with post-traumatic stress disorder (PTSD) after having received the minutes from its recent Type C meeting with the U.S. Food and Drug Administration (FDA). The company expects to initiate the Phase 2b program in

Aptinyx Provides Update on NYX-783 Development Program for the Treatment of Post-Traumatic Stress Disorder

BIOLASE

Xinyuan Real Estate Co Ltd

Top growth penny stocks to watch this year? Check these 3 out right now The post Best Growth Penny Stocks for 2021, Are Small-Caps Worth Watching?

Best Growth Penny Stocks for 2021, Are Small-Caps Worth Watching?

Aptinyx Inc. (APTX) CEO Norbert Riedel on Q1 2021 Results - Earnings Call Transcript

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today reported financial results for the first quarter of 2021 and highlighted recent progress across the company's pipeline of novel, clinical-stage, NMDA receptor modulators. “We have made excellent progress across our clinical-stage programs over the past few months,” said Norbert Riedel, Ph.D., chief execu

Aptinyx Reports First Quarter 2021 Financial Results and Highlights

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the election of Joan W. Miller, M.D., to the company's Board of Directors. Dr. Miller currently serves as the David Glendenning Cogan Professor of Ophthalmology and Chair of the Department of Ophthalmology at Harvard Medical School, as well as Chief of Ophthalmology at both Massachuse

Aptinyx Appoints Joan W. Miller, M.D.

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Thursday, May 13, 2021 at 5:00 p.m. ET to report first quarter 2021 financial results and discuss recent business highlights. To access the live conference call, please dial (833) 772-0394 (domestic) or (236) 738-2205 (i

Aptinyx to Report First Quarter 2021 Financial Results on Thursday, May 13, 2021

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today presented additional data from its exploratory Phase 2 study of NYX-783 in patients with post-traumatic stress disorder (PTSD) at the Society of Biological Psychiatry (SOBP) Annual Meeting being held virtually April 29 - May 1, 2021. The Phase 2 study evaluated NYX-783 in 153 patients with PTSD

News for Aptinyx Inc Stock (APTX)